Effects of radiotherapy and chemotherapy on sister chromatid exchanges in peripheral lymphocytes of the patients with gynecologic cancer.

Xu, Zhida; Yajima, Akira; Abe, Yoichi; Soh, Kan-Ichi; Ozawa, Nobuki; Takabayashi, T.; Sato, Shinji; Uehara, Shigeki; Suzuki, Masakuni

doi:10.1620/tjem.141.175

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is thought that the extent of genetic damage in surrogate cells, such as peripheral lymphocytes, correlates with similar events in the targeted tissues (Mourelatos, 1996). Studies have revealed structural chromosomal damage in peripheral blood lymphocytes after chemotherapy in patients with various types of cancer (Xu et al, 1983;Bilban-Jakopin, 2000;Bilban-Jakopin and Bilban, 2001). In the present study, the administration of chemotherapy was found to induce genotoxic damage in non-target cells of BC patients (Table 3).…”

Section: Discussionsupporting

confidence: 49%

Cytogenetic findings in patients diagnosed with breast cancer having undergone adjuvant chemotherapy regimens

Kosar

Koçer

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

The aim of the present study was to investigate DNA damage in peripheral blood lymphocytes of breast cancer (BC) patients before and after administration of chemotherapy. We analyzed the frequency of sister chromatid exchange (SCE), occurrence of micronuclei (MN), and lymphocyte proliferation rate index (PRI) as cytogenetic markers in 28 female BC patients before and after chemotherapy, and in 20 age-matched healthy female volunteers. Prior to treatment, BC patients showed significantly increased background levels of SCE and MN, and lowered PRIs compared to healthy women. In comparison with pre-treatment levels, SCE and MN frequencies were significantly elevated and PRI reduced in blood samples collected after chemotherapy. Our findings indicate that SCE, MN, and PRI may serve as sensitive biomarkers for routine detection of the genetic abnormalities that may occur following administration of antineoplastic drugs in the clinical setting, as well as for the monitoring of high-risk patients receiving chemotherapy for BC.

show abstract

Section: Discussionsupporting

confidence: 49%